
    
      This study will evaluate the potential therapeutic benefit of VentaProst in treating patients
      with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a
      double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients
      compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst
      given over 10 days at varying doses.
    
  